Centiva Capital’s Arcus Biosciences RCUS Stock Holding History

Centiva Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-34,984	Closed	-$711K	–	2021
2023 Q2	$711K	Buy	+34,984	New	+$666K	0.02%	685

Other funds holding RCUS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Centiva Capital's RCUS Position: Q3 2023 in Review

Centiva Capital sold out of Arcus Biosciences (RCUS) in Q3 2023, closing a stake of 34,984 shares — an estimated $711K sold.

Centiva Capital first reported a position in RCUS in Q2 2023 and held it in 1 quarter. The position peaked at $711K in Q2 2023. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2023.

Centiva Capital reported no remaining Arcus Biosciences position as of Q3 2023 after selling out during the quarter.
Centiva Capital sold 34,984 Arcus Biosciences shares in Q3 2023, an estimated $711K.
Centiva Capital first reported a position in Arcus Biosciences in Q2 2023 and held it in 1 quarter.
Centiva Capital's Arcus Biosciences position peaked at $711K in Q2 2023.
187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2023.

Based on Centiva Capital's 13F filing for Q3 2023, filed 14 Nov 2023.